These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

660 related items for PubMed ID: 29085193

  • 41. No lipiodol, no beads-another transcatheter arterial chemoembolization (TACE) with fine cisplatin powder and porous gelatin particles for TACE-naïve, multifocal, up-to-seven out hepatocellular carcinoma.
    Sato R, Moriguchi M, Saiga A, Asahara K, Aramaki T.
    Cancer Med; 2024 Jul; 13(14):e7446. PubMed ID: 39015047
    [Abstract] [Full Text] [Related]

  • 42. Individualized treatment models based on blood supply characteristics in hepatocellular carcinoma using color Doppler hemodynamics.
    Si Q, Mu H, Yan G, Qian X, Xu C, Wang X, Tong W.
    Hepatogastroenterology; 2007 Mar; 54(74):334-41. PubMed ID: 17523269
    [Abstract] [Full Text] [Related]

  • 43. Superselective Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma: Rationale, Technique, and Outcome.
    Miyayama S, Matsui O.
    J Vasc Interv Radiol; 2016 Sep; 27(9):1269-1278. PubMed ID: 27345337
    [Abstract] [Full Text] [Related]

  • 44. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres® in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres® Transarterial Chemoembolization in Liver Cancer (CTILC) Study.
    Sun J, Zhou G, Xie X, Gu W, Huang J, Zhu D, Hu W, Hou Q, Shi C, Li T, Zhang X, Ji W, Ying S, Peng Z, Zhou J, Yu Z, Ji J, Du H, Guo X, Fang J, Han J, Xu H, Sun Z, Yu W, Shao G, Wu X, Hu H, Li L, Zheng J, Luo J, Chen Y, Cao G, Hu T.
    Oncol Res; 2020 Feb 07; 28(1):75-94. PubMed ID: 31558180
    [Abstract] [Full Text] [Related]

  • 45. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept.
    Abajian A, Murali N, Savic LJ, Laage-Gaupp FM, Nezami N, Duncan JS, Schlachter T, Lin M, Geschwind JF, Chapiro J.
    J Vasc Interv Radiol; 2018 Jun 07; 29(6):850-857.e1. PubMed ID: 29548875
    [Abstract] [Full Text] [Related]

  • 46. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients.
    Ippolito D, Fior D, Bonaffini PA, Capraro C, Leni D, Corso R, Sironi S.
    Eur J Radiol; 2014 Sep 07; 83(9):1665-71. PubMed ID: 24962900
    [Abstract] [Full Text] [Related]

  • 47. Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
    Zhang Y, Fan W, Wang Y, Lu L, Fu S, Yang J, Huang Y, Yao W, Li J.
    Oncologist; 2015 Dec 07; 20(12):1417-24. PubMed ID: 26446238
    [Abstract] [Full Text] [Related]

  • 48. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
    Wang Z, Chen R, Duran R, Zhao Y, Yenokyan G, Chapiro J, Schernthaner R, Radaelli A, Lin M, Geschwind JF.
    Cardiovasc Intervent Radiol; 2015 Dec 07; 38(6):1548-56. PubMed ID: 26001366
    [Abstract] [Full Text] [Related]

  • 49. Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study.
    Chen J, Lai L, Lin Q, Huang W, Cai M, Zhu K, Huang M.
    Oncotarget; 2017 Jan 03; 8(1):408-417. PubMed ID: 27880724
    [Abstract] [Full Text] [Related]

  • 50. Hepatocellular carcinoma: initial tumour response after short-term and long-interval chemoembolization with drug-eluting beads using modified RECIST.
    Syha R, Ketelsen D, Heller S, Schmehl J, Mangold S, Heuschmid M, Springer F, Claussen CD, Brechtel K.
    Eur J Gastroenterol Hepatol; 2012 Nov 03; 24(11):1325-32. PubMed ID: 22872074
    [Abstract] [Full Text] [Related]

  • 51. Transarterial chemoembolization for hepatocellular carcinoma: An old method, now flavor of the day.
    Boulin M, Delhom E, Pierredon-Foulongne MA, Cercueil JP, Guiu B.
    Diagn Interv Imaging; 2015 Jun 03; 96(6):607-15. PubMed ID: 25998996
    [Abstract] [Full Text] [Related]

  • 52. Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study.
    Malagari K, Pomoni M, Moschouris H, Kelekis A, Charokopakis A, Bouma E, Spyridopoulos T, Chatziioannou A, Sotirchos V, Karampelas T, Tamvakopoulos C, Filippiadis D, Karagiannis E, Marinis A, Koskinas J, Kelekis DA.
    Cardiovasc Intervent Radiol; 2014 Feb 03; 37(1):165-75. PubMed ID: 24263774
    [Abstract] [Full Text] [Related]

  • 53. Sequential transcatheter arterial chemoembolization and portal vein embolization before right hemihepatectomy in patients with hepatocellular carcinoma.
    Park GC, Lee SG, Yoon YI, Sung KB, Ko GY, Gwon DI, Jung DH, Jung YK.
    Hepatobiliary Pancreat Dis Int; 2020 Jun 03; 19(3):244-251. PubMed ID: 32414576
    [Abstract] [Full Text] [Related]

  • 54. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
    Shim JH, Han S, Shin YM, Yu E, Park W, Kim KM, Lim YS, Lee HC.
    J Vasc Interv Radiol; 2013 Mar 03; 24(3):316-25. PubMed ID: 23312990
    [Abstract] [Full Text] [Related]

  • 55. Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial.
    Aramaki O, Takayama T, Moriguchi M, Sakamoto H, Yodono H, Kokudo N, Yamanaka N, Kawasaki S, Sasaki Y, Kubota K, Otsuji E, Tanaka S, Matsuyama Y, Fujii M, ACE 500 study group.
    Eur J Cancer; 2021 Nov 03; 157():373-382. PubMed ID: 34563992
    [Abstract] [Full Text] [Related]

  • 56. Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma.
    Tawada A, Chiba T, Ooka Y, Kanogawa N, Saito T, Motoyama T, Ogasawara S, Suzuki E, Kanai F, Yoshikawa M, Yokosuka O.
    Anticancer Res; 2015 Jan 03; 35(1):549-54. PubMed ID: 25550601
    [Abstract] [Full Text] [Related]

  • 57. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.
    Seki A, Hori S.
    Cardiovasc Intervent Radiol; 2012 Jun 03; 35(3):555-62. PubMed ID: 21562932
    [Abstract] [Full Text] [Related]

  • 58. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ, Dhanasekaran R, El-Rayes BF, Kauh JS, Maithel SK, Chen Z, Kim HS.
    J Vasc Interv Radiol; 2013 Mar 03; 24(3):307-15. PubMed ID: 23375519
    [Abstract] [Full Text] [Related]

  • 59. Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma.
    Roth GS, Teyssier Y, Abousalihac M, Seigneurin A, Ghelfi J, Sengel C, Decaens T.
    World J Gastroenterol; 2020 Jan 21; 26(3):324-334. PubMed ID: 31988592
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.